BPC157

  • CasNo:137525-51-0
  • Molecular Formula:C62H98 N16 O22
  • Purity:
  • Molecular Weight:1419.54
Inquiry

Product Details

BPC157 Cas No.137525-51-0 Competitive Price Good Supplier

  • Molecular Formula:C62H98 N16 O22
  • Molecular Weight:1419.54
  • Vapor Pressure:0mmHg at 25°C 
  • Boiling Point:1802.9°Cat760mmHg 
  • PKA:3.36±0.10(Predicted) 
  • Flash Point:1044.2°C 
  • PSA:561.45000 
  • Density:1.366g/cm3 
  • LogP:-0.44950 

BPC 157(Cas 137525-51-0) Usage

Description

BPC 157 is not a steroid. Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice and has no reported toxicity.

Uses

BPC-157 is often most used to treat stomach and intestinal conditions such as inflamed intestinal epithelium (leaky gut), eosinophilic esophagitis, and inflammatory bowel disease; however, its abilities to improve tpe 1 collagen and increase blood flow via angiogenesis means it is a powerful peptide for wound healing and overall regeneration following damage. Notably, BPC-157 aids in alleviating joint pain, old injuries and those looking to improve joint mobility. BPC-157 can be used in conjunction with other therapies to enhance and increase your results.

benefits

There have been many positive effects noted by those who have experimented with the use of BPC-157 for issues including bone healing, ligament healing, general regenerative properties and more. 

Biological Activity

BPC 157 is a gut peptide and possesses free radical scavenging activity. This peptide stimulates nitric oxide synthase generation and therefore offers gastric cytoprotection. Unlike other peptides, BPC 157 is effective without a carrier. It participates in muscle healing and is used in the treatment of gastrocnemius muscle complex.BPC 157 is a stable gastric pentadecapeptide that exhibit anti-ulcer and wounds/fistulas healing properties. BPC 157 reduces immediate and delayed damage induced brain trauma and improves nerve regeneration after transection. BPC 157 displays antianxiety and antidepressant effects. It appears that BPC 157 promotes proliferation, migration, and tube formation of human umbilical vein endothelial cells through activation of ERK1/2 phosphorylation.

Clinical Use

Therapeutically, the synthetically produced peptide BPC-157 is not currently approved for use as a human drug. It is an experimental compound that has been investigated for inflammatory bowel disease and soft tissue healing, although there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions. It is important to realize that these are unproven claims, and that the use of BPC-157 for these or any other reasons is not supported by medical literature or by any medical associations.Other websites advertise BPC-157 as a “research chemical” that is “not for human use,” and yet, the same websites have suggestions for how someone could use it. Athletes are advised to never use a product that is marketed for “research only.”

Side effects

BPC-157 side effects (if any) are usually mild, especially when used at the proper dosage. Regardless, it is worth noting that research on BPC is still limited. We can however look to side effects associated with other peptides to hypothesize what we might need to look out for.Flashes of very hot or cold temperatureChanges to appetite and/or weightDizzinessFatigueHeadaches

Safety

BPC-157 is generally considered safe for use. As it is naturally found in gastric juices, it should be well tolerated by the body in theory. It is however important to note that human clinical trials are still limited and side effects, as above, have been reported. 

Dosage forms

BPC-157 comes in two different forms: oral capsules and an injectable form. As an oral capsule, BPC-157 is best suited for gut restoration and for addressing intestinal problems. On the other hand, BPC-157 injectable is the preferred route of administration for inflammation, muscle sprains, ligament damage, and pain.

InChI:InChI=1/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35?,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1

137525-51-0 Relevant articles

Stable gastric pentadecapeptide BPC 157-NO-system relation

Sikiric, Predrag; Seiwerth, Sven; Rucman, Rudolf; Turkovic, Branko; Stancic Rokotov, Dinko; Brcic, Luka; Sever, Marko; Klicek, Robert; Radic, Bozo; Drmic, Domagoj; Ilic, Spomenko; Kolenc, Danijela; Aralica, Gorana; Stupnisek, Mirjana; Suran, Jelena; Barisic, Ivan; Dzidic, Senka; Vrcic, Hrvoje; Sebecic, Bozidar

, Current Pharmaceutical Design, Volume 20, Number 7, 2014, pp. 1126-1135(10)

We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. Hypothesis, that BPC 157 (since formed constitutively in the gastric mucosa, stable in human gastric juice.

Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157

Mario Staresinic, Igor Petrovic, Tomislav Novinscak, Ivana Jukic, Damira Pevec, Slaven Suknaic, Neven Kokic, Lovorka Batelja, Luka Brcic, Alenka Boban-Blagaic, Zdenka Zoric, Domagoj Ivanovic, Marko Ajduk, Bozidar Sebecic, Leonardo Patrlj, Tomislav Sosa, Gojko Buljat, Tomislav Anic, Sven Seiwerth, Predrag Sikiric

, Journal of Orthopaedic Research, Volume24, Issue5 May 2006 Pages 1109-1117

Initially, stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, PL-10, PLD-116, PL 14736 Pliva, Croatia; in trials for inflammatory bowel disease; wound treatment; no toxicity reported; effective alone without carrier) also superiorly accelerates the healing of transected Achilles tendon. BPC 157 (10 µg, 10 ng, 10 pg/kg) is given intraperitoneally, once daily; the first application 30 min posttransection, the final 24 h before sacrifice.